Esperion Therapeutics Inc
NASDAQ: ESPR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-06-02
Esperion Therapeutics Inc (ESPR) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 1999 | — | $-10.67M | — | — | — |
| 2000 | $2000.00 | $-27.58M | -39,200.00% | -1,378,600.00% | -1,378,800.00% |
| 2001 | — | $-24.93M | — | — | — |
| 2002 | — | $-28.73M | — | — | — |
| 2011 | — | $-10.82M | — | — | — |
| 2012 | — | $-11.74M | — | — | — |
| 2013 | $4.98B | $-26.09M | 100.00% | -0.46% | -0.52% |
| 2014 | $0.00 | $-36.38M | — | — | — |
| 2015 | $0.00 | $-49.78M | — | — | — |
| 2016 | $0.00 | $-74.98M | — | — | — |
| 2017 | $0.00 | $-166.99M | — | — | — |
| 2018 | $184.47M | $-201.81M | 100.00% | -110.90% | -109.40% |
| 2019 | $148.36M | $-97.17M | 100.00% | -62.75% | -65.49% |
| 2020 | $227.55M | $-143.55M | 98.95% | -53.35% | -63.09% |
| 2021 | $78.45M | $-269.11M | 81.88% | -289.02% | -343.04% |
| 2022 | $75.47M | $-233.66M | 64.27% | -237.83% | -309.58% |
| 2023 | $116.33M | $-209.25M | 62.81% | -133.72% | -179.87% |
| 2024 | $332.31M | $-51.74M | 79.36% | 16.37% | -15.57% |
| 2025 | $403.13M | $-22.68M | 67.95% | 14.95% | -5.63% |
Frequently asked questions
What is Esperion Therapeutics Inc's revenue?
Esperion Therapeutics Inc's trailing twelve-month revenue is $418.24M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is ESPR?
In its most recent fiscal year, ESPR ran a gross margin of 67.95%, an operating margin of 14.95%, and a net margin of -5.63%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does ESPR generate?
ESPR produced $-13.28M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is ESPR's balance sheet healthy?
ESPR holds $167.85M in cash and equivalents against $249.48M in long-term debt, on $-301.96M of shareholder equity. That debt is best read against the cash flow the business throws off each year.